비교리스트

 카트 문의
시장보고서
상품코드
1363467

세계의 전립선 비대증(BPH) 치료기기 시장 규모, 점유율, 동향 분석 보고서 : 치료별, 시술별, 제품별, 최종 용도별, 지역별, 부문별 - 예측(2023-2030년)

Benign Prostatic Hyperplasia Treatment Devices Market Size, Share & Trends Analysis Report By Treatment, By Procedure, By Product (Resectoscopes, Urology Laser), By End-use, By Region, And Segment Forecasts, 2023 - 2030
발행일: | 리서치사: Grand View Research | 페이지 정보: 영문 120 Pages | 배송안내 : 2-10일 (영업일 기준)

    
    
    




※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

전립선 비대증(BPH) 치료기기 시장의 성장과 동향 :

Grand View Research, Inc.의 최신 보고서에 따르면 세계 전립선 비대증 치료기기 시장 규모는 2023년부터 2030년에 걸쳐 8.90%의 CAGR로 성장을 지속하여 2030년에는 27억 9,000만 달러에 달할 것으로 예측됩니다.

전립선 비대증(BPH) 치료에 사용되는 로봇 시스템 애플리케이션 증가, 아쿠아블레이션 치료 발전, 질병 조기 진단, 건강의식 향상이 시장 성장의 원동력이 되었습니다. 전립선 비대증의 유병률 상승과 새로운 치료법 시장 개척이 진행됨에 따라 전립선 비대증 치료기기 시장은 세계적으로 확대될 것으로 예상됩니다.

아쿠아블레이션 수술는 물과 고주파 에너지를 결합한 시스템을 사용합니다. 일반적으로 수술에는 국소 마취 또는 전신 마취가 사용됩니다. 전립선 비대증의 개복 수술을 통한 치료와 비교할 때, 아쿠아블레이션 수술은 출혈이 적고 카테터 치료 기간이 짧아지는 등 많은 이점이 있습니다. 예를 들어, 2023년 4월 PROCEPT BioRobotics Corporation에 따르면, 5년간 진행한 WATER II Study의 결과를 통해, 전립선 비대증(BPH)에 대한 최소 침습 로봇 수술법인 아쿠아블레이션 수술은 80-150mL의 전립선을 가진 남성에서 안전하고 효과적으로 지속적인 증상을 완화하고, 최대 5년간 성 기능을 유지하는 것으로 나타났습니다. Journal of Urology 잡지에 발표된 이 연구는 환자의 증상과 QOL이 시간이 지남에 따라 크게 개선되고 있음을 보여주었습니다.

주요 연구자들은 전립선 비대증 치료용 임플란트의 개발에도 종사하고 있습니다. 좋은 결과의 임상 연구는 시장 성장에 긍정적인 영향을 미칩니다. 예를 들어, Urology Times에 게재된 기사에 따르면 ProVerum Limited는 2022년 6월에 전립선 비대증 환자용 니티놀제 익스팬더 장치를 발명했습니다. 획기적인 ProVee 시스템을 사용한 첫 번째 치료는 Avant Concierge Urology의 주요 ProVIDE 테스트에서 성공했습니다. ProVee라고 불리는 자기 확장형 임플란트는 착용 후 곧 제한된 요도를 부드럽게 성형하여 퍼져 소변량을 증가시키고 환자의 삶의 질을 향상시킵니다. 따라서 이러한 진보로 전립선 비대증 치료기기 수요는 가까운 미래에 증가할 것으로 보입니다.

전립선 비대증(BPH) 치료기기 시장 보고서 하이라이트

  • 치료법별로는 최소 침습 수술이 2022년에 72.16%의 수익 점유율로 전립선 비대증(BPH) 치료 기기 시장을 독점했습니다.
  • 절차별로는 요도 전립선 절제술(TURP) 부문이 2022년 25.32%의 수익 점유율로 시장을 독점했습니다. TURP 치료는 최적표준이며 가장 효과적인 전립선 비대증 치료로 간주됩니다.
  • 최종 용도별로는 병원이 2022년 64.77%로 시장의 대부분을 차지했습니다. 수술, 치료 및 처치를 위해 병원에 입원하는 환자가 증가하고 있기 때문에 가까운 미래에 신경혈관 카테터에 대한 수요가 높아질 것으로 예상됩니다.
  • 북미는 2022년 34.95%의 최대 수익 점유율로 시장을 선도했습니다. 최소 침습 수술에 대한 수요 증가와 건강 관리 인프라 개선을 위한 정부 계획 증가는 시장 성장을 가속하는 주요 요인 중 하나입니다. 또한 기술의 진보와 새로운 비침습 기술의 혁신은 이 부문에 유리한 기회를 가져올 것으로 보입니다.

목차

제1장 조사 방법과 범위

제2장 주요 요약

제3장 전립선 비대증(BPH) 치료기기 시장의 변수, 동향 및 범위

  • 시장 계통 전망
    • 상위 시장 전망
    • 관련/부수 시장 전망
  • 시장 역학
    • 시장 성장 촉진요인 분석
    • 시장 성장 억제요인 분석
  • 전립선 비대증(BPH) 치료기기 시장 분석 도구
    • 업계 분석 - Porter's Five Forces 분석
    • PESTEL 분석
    • COVID-19의 영향 분석

제4장 전립선비대증(BPH) 치료기기 시장 : 치료별 추정·동향 분석

  • 정의와 범위
  • 치료 시장 점유율, 2018년 및 2030년
  • 부문 대시보드
  • 세계 시장 전망
  • 시장 규모, 예측 및 동향 분석, 2023년부터 2030년까지

제5장 전립선 비대증(BPH) 치료기기 시장 : 시술별 추정·동향 분석

  • 정의와 범위
  • 절차 시장 점유율, 2018년 및 2030년
  • 부문 대시보드
  • 세계 시장 전망
  • 시장 규모, 예측 및 동향 분석, 2023년부터 2030년까지

제6장 전립선 비대증(BPH) 치료기기 시장 : 제품별 추정·동향 분석

  • 정의와 범위
  • 제품 시장 점유율, 2018년 및 2030년
  • 부문 대시보드
  • 세계 시장 전망
  • 시장 규모, 예측 및 동향 분석, 2018년부터 2030년까지

제7장 전립선 비대증(BPH) 치료기기 시장 : 최종 사용별 추정·동향 분석

  • 정의와 범위
  • 최종 용도 시장 점유율, 2018년 및 2030년
  • 부문 대시보드
  • 세계 시장 전망
  • 시장 규모, 예측 및 동향 분석, 2018년부터 2030년까지

제8장 전립선비대증(BPH) 치료기기 시장 : 지역별 추정·동향 분석

  • 지역 시장 점유율 분석, 2018년 및 2030년
  • 지역 시장 대시보드
  • 세계 지역 시장 현황
  • 2023년부터 2030년까지 시장 규모와 예측 동향 분석 :
  • 북미
    • 미국
    • 캐나다
  • 유럽
    • 영국
    • 독일
    • 프랑스
    • 이탈리아
    • 스페인
    • 노르웨이
    • 스웨덴
    • 덴마크
  • 아시아태평양
    • 일본
    • 중국
    • 인도
    • 호주
    • 한국
    • 태국
  • 라틴아메리카
    • 브라질
    • 멕시코
    • 아르헨티나
  • 중동 및 아프리카
    • 남아프리카
    • 사우디아라비아
    • 아랍에미리트(UAE)
    • 쿠웨이트

제9장 경쟁 구도

  • 주요 시장 진출기업에 의한 최근의 동향과 영향 분석
  • 회사/경쟁의 분류
    • 이노베이터
  • 벤더 상황
    • 주요 유통업체 및 채널 파트너 목록
    • 주요 고객
    • 주요 시장 점유율 분석, 2022년
    • Karl Storz
    • Boston Scientific Corporation
    • Olympus America
    • Endo Pharmaceuticals Inc.
    • Biolitec AG
    • Medifocus
    • Cook Medical
    • Teleflex Incorporated
    • Urotronic
    • Coloplast Corp
    • Richard Wolf GmbH
    • PROCEPT BioRobotics Corporation
JHS 23.10.30

Benign Prostatic Hyperplasia Treatment Devices Market Growth & Trends:

The global benign prostatic hyperplasia treatment devices market size is anticipated to reach USD 2.79 billion by 2030, registering at a CAGR of 8.90% from 2023 to 2030, according to a new report by Grand View Research, Inc.. Increasing application of the robotic system used for the benign prostatic hyperplasia (BPH) treatments, enhancements in the aquablation therapy, early disease diagnosis and increasing health awareness among people drive the market growth. Due to the rising prevalence of BPH and the ongoing development of novel therapy alternatives, the BPH treatment device market is anticipated to expand globally.

Aquablation therapy involves the use of a system that combines water and radiofrequency energy. Normally, either local or general anesthesia is used during the surgery. When compared to the open surgical treatments for BPH, aquablation therapy has a number of advantages, including less bleeding and a shorter catheterization period. For instance, in April 2023, according to PROCEPT BioRobotics Corporation, 5-year results from the WATER II Study showed that Aquablation therapy, a minimally invasive robotic surgical procedure for benign prostatic hyperplasia, safely and effectively relieved persistent symptoms in men with large prostates (80 to 150 mL) and maintains sexual function for up to five years. The study, which was released in the Journal of Urology, showed that patients' symptoms and quality of life kept improving significantly over time.

The key players are also involved in developing implants for the treatment of benign prostatic hyperplasia. The positive outcomes from the clinical studies have a positive impact on the market growth. For instance, as per the article published in Urology Times, the company ProVerum Limited invented the nitinol expander device for people with BPH in June 2022. The first treatment using the revolutionary ProVee System was successfully conducted in the key ProVIDE trial at Avant Concierge Urology. A self-expanding implant called ProVee gently reshapes and widens a restricted urethra to increase urine flow shortly after it is in place and also improves the quality of life in the patients. Thus, due to such advancements, the demand for Benign Prostatic Hyperplasia (BPH) treatment devices will increase in the near future.

Benign Prostatic Hyperplasia Treatment Devices Market Report Highlights:

  • Based on treatment, minimal invasive surgery dominated the BPH treatment devices market with a revenue share of 72.16 % in 2022, owing to the less postpartum pain and discomfort that may result from smaller incisions and less tissue manipulation
  • Based on procedure, Transurethral Resection of the Prostate (TURP) segment dominated the market in 2022 with a revenue share of 25.32%. The TURP procedure is considered a golden standard and the most effective BPH treatment
  • Based on end-use, hospitals held a majority share of the market with 64.77% in 2022. The increasing number of patients being admitted to hospitals due to surgeries, therapies, and treatments is expected to increase the demand for neurovascular catheters in the near future
  • North America led the market with the maximum revenue share of 34.95% in 2022. Rising demand for minimally invasive surgeries and rising government initiatives for improving healthcare infrastructures are among the key factors driving the market growth. In addition, technological advancement and innovation of new noninvasive techniques will create lucrative opportunities for the segment

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
    • 1.1.1. Treatment
    • 1.1.2. Procedure
    • 1.1.3. Product
    • 1.1.4. End-use
    • 1.1.5. Regional scope
    • 1.1.6. Estimates and forecast timeline
  • 1.2. Research Methodology
  • 1.3. Information Procurement
    • 1.3.1. Purchased database
    • 1.3.2. GVR's internal database
    • 1.3.3. Secondary sources
    • 1.3.4. Primary research
    • 1.3.5. Details of primary research
      • 1.3.5.1. Data for primary interviews in North America
      • 1.3.5.2. Data for primary interviews in Europe
      • 1.3.5.3. Data for primary interviews in Asia Pacific
      • 1.3.5.4. Data for primary interviews in Latin America
      • 1.3.5.5. Data for Primary interviews in MEA
  • 1.4. Information or Data Analysis
    • 1.4.1. Data analysis models
  • 1.5. Market Formulation & Validation
  • 1.6. Model Details
    • 1.6.1. Commodity flow analysis (Model 1)
      • 1.6.1.1. Approach 1: Commodity flow approach
    • 1.6.2. Volume price analysis (Model 2)
      • 1.6.2.1. Approach 2: Volume price analysis
  • 1.7. List of Secondary Sources
  • 1.8. List of Primary Sources
  • 1.9. Objectives
    • 1.9.1. Objective 1
    • 1.9.2. Objective 2

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Treatment outlook
    • 2.2.2. Procedure outlook
    • 2.2.3. Product outlook
    • 2.2.4. End-use outlook
    • 2.2.5. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Benign Prostatic Hyperplasia (BPH) Treatment Device Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Increasing geriatric population
      • 3.2.1.2. Increasing prevalence of obesity and diabetes
      • 3.2.1.3. Shift towards minimally invasive prostatic procedures
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. High cost of the treatment
      • 3.2.2.2. Strict government regulations
  • 3.3. Benign Prostatic Hyperplasia (BPH) Treatment Device Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape
    • 3.3.3. Covid-19 Impact Analysis

Chapter 4. Benign Prostatic Hyperplasia (BPH) Treatment Device Market: Treatment Estimates & Trend Analysis

  • 4.1. Definitions and Scope
    • 4.1.1. Minimal Invasive Surgery
    • 4.1.2. Invasive Surgery
  • 4.2. Treatment Market Share, 2018 & 2030
  • 4.3. Segment Dashboard
  • 4.4. Global Benign Prostatic Hyperplasia (BPH) Treatment Market by Treatment Outlook
  • 4.5. Market Size & Forecasts and Trend Analyses, 2023 to 2030 for the following
    • 4.5.1. Minimal Invasive Surgery
      • 4.5.1.1. Minimal invasive surgery market estimates and forecast 2018 to 2030 (USD Million)
    • 4.5.2. Invasive Surgery
      • 4.5.2.1. Invasive surgery market estimates and forecast 2018 to 2030s, (USD Million)

Chapter 5. Benign Prostatic Hyperplasia (BPH) Treatment Device Market: Procedure Estimates & Trend Analysis

  • 5.1. Definitions and Scope
    • 5.1.1. Transurethral Microwave Thermotherapy
    • 5.1.2. Transurethral Needle Ablation of the Prostate
    • 5.1.3. Prostatic Urethral Lift
    • 5.1.4. Water Vapor Therapy
    • 5.1.5. Robot-Assisted Laparoscopic Prostatectomy
    • 5.1.6. Prostate Laser Surgery
    • 5.1.7. Aquablation Therapy
    • 5.1.8. Prostatic Artery Embolization
    • 5.1.9. Open Prostatectomy
    • 5.1.10. Transurethral Resection of the Prostate
    • 5.1.11. Bipolar Enucleation of Prostate
    • 5.1.12. Transurethral Incision of the Prostate
    • 5.1.13. High-Intensity Focused Ultrasound
  • 5.2. Procedure Market Share, 2018 & 2030
  • 5.3. Segment Dashboard
  • 5.4. Global Benign Prostatic Hyperplasia (BPH) Treatment Device Market by Procedure Outlook
  • 5.5. Market Size & Forecasts and Trend Analyses, 2023 to 2030 for the following
    • 5.5.1. Transurethral Microwave Thermotherapy
      • 5.5.1.1. Transurethral microwave thermotherapy market estimates and forecast 2018 to 2030 (USD Million)
    • 5.5.2. Transurethral Needle Ablation of the Prostate
      • 5.5.2.1. Transurethral needle ablation of the prostate market estimates and forecast 2018 to 2030 (USD Million
    • 5.5.3. Prostatic Urethral Lift
      • 5.5.3.1. Prostatic urethral lift market estimates and forecast 2018 to 2030 (USD Million)
    • 5.5.4. Water Vapour Therapy
      • 5.5.4.1. Water vapour therapy market estimates and forecast 2018 to 2030 (USD Million)
    • 5.5.5. Robot-Assisted Laparoscopic Prostatectomy
      • 5.5.5.1. Robot-assisted laparoscopic prostatectomy market estimates and forecast 2018 to 2030 (USD Million)
    • 5.5.6. Prostate Laser Surgery
      • 5.5.6.1. Prostate laser surgery market estimates and forecast 2018 to 2030 (USD Million)
    • 5.5.7. Aquablation Therapy
      • 5.5.7.1. Aquablation therapy market estimates and forecast 2018 to 2030 (USD Million)
    • 5.5.8. Prostatic Artery Embolization
      • 5.5.8.1. Prostatic artery embolization market estimates and forecast 2018 to 2030 (USD Million)
    • 5.5.9. Open Prostatectomy
      • 5.5.9.1. Open prostatectomy market estimates and forecast 2018 to 2030 (USD Million)
    • 5.5.10. Transurethral Resection of the Prostate
      • 5.5.10.1. Transurethral resection of the prostate market estimates and forecast 2018 to 2030 (USD Million)
    • 5.5.11. Bipolar Enucleation of Prostate
      • 5.5.11.1. Bipolar enucleation of prostate market estimates and forecast 2018 to 2030 (USD Million)
    • 5.5.12. Transurethral Incision of the Prostate
      • 5.5.12.1. Transurethral incision of the prostate market estimates and forecast 2018 to 2030 (USD Million)
    • 5.5.13. High-Intensity Focused Ultrasound
      • 5.5.13.1. High-intensity focused ultrasound market estimates and forecast 2018 to 2030 (USD Million)

Chapter 6. Benign Prostatic Hyperplasia (BPH) Treatment Device Market: Product Estimates & Trend Analysis

  • 6.1. Definitions and Scope
    • 6.1.1. Resectoscopes
    • 6.1.2. Urology Laser
    • 6.1.3. Radiofrequency Ablation
    • 6.1.4. Electrodes
    • 6.1.5. Catheter
    • 6.1.6. Prostatic Stents
    • 6.1.7. Implants
    • 6.1.8. Others
  • 6.2. Product Market Share, 2018 & 2030
  • 6.3. Segment Dashboard
  • 6.4. Global Benign Prostatic Hyperplasia (BPH) Treatment Device Market by Product Outlook
  • 6.5. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 6.5.1. Resectoscopes
      • 6.5.1.1. Resectoscopes market estimates and forecast 2018 to 2030 (USD Million)
    • 6.5.2. Urology Laser
      • 6.5.2.1. Urology laser market estimates and forecast 2018 to 2030 (USD Million)
    • 6.5.3. Radiofrequency Ablation
      • 6.5.3.1. Radiofrequency ablation market estimates and forecast 2018 to 2030 (USD Million)
    • 6.5.4. Electrodes
      • 6.5.4.1. Electrodes market estimates and forecast 2018 to 2030 (USD Million)
    • 6.5.5. Catheter
      • 6.5.5.1. Catheter market estimates and forecast 2018 to 2030 (USD Million)
    • 6.5.6. Prostatic Stents
      • 6.5.6.1. Prostatic stents market estimates and forecast 2018 to 2030 (USD Million)
    • 6.5.7. Implants
      • 6.5.7.1. Implants market estimates and forecast 2018 to 2030 (USD Million)
    • 6.5.8. Others
      • 6.5.8.1. Others market estimates and forecast 2018 to 2030 (USD Million)

Chapter 7. Benign Prostatic Hyperplasia (BPH) Treatment Device Market: End-use Estimates & Trend Analysis

  • 7.1. Definitions and Scope
    • 7.1.1. Hospitals
    • 7.1.2. Specialty Facilities
    • 7.1.3. Research and Academic Institute
  • 7.2. End-use Market Share, 2018 & 2030
  • 7.3. Segment Dashboard
  • 7.4. Global Benign Prostatic Hyperplasia (BPH) Treatment Device by End-use Outlook
  • 7.5. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 7.5.1. Hospitals
      • 7.5.1.1. Hospitals market estimates and forecast 2018 to 2030 (USD Million)
    • 7.5.2. Specialty facilities
      • 7.5.2.1. Specialty facilities market estimates and forecast 2018 to 2030 (USD Million)
    • 7.5.3. Research and Academic Institute
      • 7.5.3.1. Research and academic institute market estimates and forecast 2018 to 2030 (USD Million)

Chapter 8. Benign Prostatic Hyperplasia (BPH) Treatment Device Market: Regional Estimates & Trend Analysis

  • 8.1. Regional Market Share Analysis, 2018 & 2030
  • 8.2. Regional Market Dashboard
  • 8.3. Global Regional Market Snapshot
  • 8.4. Market Size, & Forecasts Trend Analysis, 2023 to 2030:
  • 8.5. North America
    • 8.5.1. U.S.
      • 8.5.1.1. U.S. market estimates and forecast, 2018 - 2030 (USD Million)
    • 8.5.2. Canada
      • 8.5.2.1. Canada market estimates and forecast, 2018 - 2030 (USD Million)
  • 8.6. Europe
    • 8.6.1. UK
      • 8.6.1.1. UK market estimates and forecast, 2018 - 2030 (USD Million)
    • 8.6.2. Germany
      • 8.6.2.1. Germany market estimates and forecast, 2018 - 2030 (USD Million)
    • 8.6.3. France
      • 8.6.3.1. France market estimates and forecast, 2018 - 2030 (USD Million)
    • 8.6.4. Italy
      • 8.6.4.1. Italy market estimates and forecast, 2018 - 2030 (USD Million)
    • 8.6.5. Spain
      • 8.6.5.1. Spain market estimates and forecast, 2018 - 2030 (USD Million)
    • 8.6.6. Norway
      • 8.6.6.1. Norway market estimates and forecast, 2018 - 2030 (USD Million)
    • 8.6.7. Sweden
      • 8.6.7.1. Sweden market estimates and forecast, 2018 - 2030 (USD Million)
    • 8.6.8. Denmark
      • 8.6.8.1. Denmark market estimates and forecast, 2018 - 2030 (USD Million)
  • 8.7. Asia Pacific
    • 8.7.1. Japan
      • 8.7.1.1. Japan market estimates and forecast, 2018 - 2030 (USD Million)
    • 8.7.2. China
      • 8.7.2.1. China market estimates and forecast, 2018 - 2030 (USD Million)
    • 8.7.3. India
      • 8.7.3.1. India market estimates and forecast, 2018 - 2030 (USD Million)
    • 8.7.4. Australia
      • 8.7.4.1. Australia market estimates and forecast, 2018 - 2030 (USD Million)
    • 8.7.5. South Korea
      • 8.7.5.1. South Korea market estimates and forecast, 2018 - 2030 (USD Million)
    • 8.7.6. Thailand
      • 8.7.6.1. Thailand market estimates and forecast, 2018 - 2030 (USD Million)
  • 8.8. Latin America
    • 8.8.1. Brazil
      • 8.8.1.1. Brazil market estimates and forecast, 2018 - 2030 (USD Million)
    • 8.8.2. Mexico
      • 8.8.2.1. Mexico market estimates and forecast, 2018 - 2030 (USD Million)
    • 8.8.3. Argentina
      • 8.8.3.1. Argentina market estimates and forecast, 2018 - 2030 (USD Million)
  • 8.9. MEA
    • 8.9.1. South Africa
      • 8.9.1.1. South Africa market estimates and forecast, 2018 - 2030 (USD Million)
    • 8.9.2. Saudi Arabia
      • 8.9.2.1. Saudi Arabia market estimates and forecast, 2018 - 2030 (USD Million)
    • 8.9.3. UAE
      • 8.9.3.1. UAE market estimates and forecast, 2018 - 2030 (USD Million)
    • 8.9.4. Kuwait
      • 8.9.4.1. Kuwait market estimates and forecast, 2018 - 2030 (USD Million)

Chapter 9. Competitive Landscape

  • 9.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 9.2. Company/Competition Categorization
    • 9.2.1. Innovators
  • 9.3. Vendor Landscape
    • 9.3.1. List of key distributors and channel partners
    • 9.3.2. Key customers
    • 9.3.3. Key company market share analysis, 2022
    • 9.3.4. Karl Storz
      • 9.3.4.1. Company overview
      • 9.3.4.2. Financial performance
      • 9.3.4.3. Product benchmarking
      • 9.3.4.4. Strategic initiatives
    • 9.3.5. Boston Scientific Corporation
      • 9.3.5.1. Company overview
      • 9.3.5.2. Financial performance
      • 9.3.5.3. Product benchmarking
      • 9.3.5.4. Strategic initiatives
    • 9.3.6. Olympus America
      • 9.3.6.1. Company overview
      • 9.3.6.2. Financial performance
      • 9.3.6.3. Product benchmarking
      • 9.3.6.4. Strategic initiatives
    • 9.3.7. Endo Pharmaceuticals Inc.
      • 9.3.7.1. Company overview
      • 9.3.7.2. Financial performance
      • 9.3.7.3. Product benchmarking
      • 9.3.7.4. Strategic initiatives
    • 9.3.8. Biolitec AG
      • 9.3.8.1. Company overview
      • 9.3.8.2. Financial performance
      • 9.3.8.3. Product benchmarking
      • 9.3.8.4. Strategic initiatives
    • 9.3.9. Medifocus
      • 9.3.9.1. Company overview
      • 9.3.9.2. Financial performance
      • 9.3.9.3. Product benchmarking
      • 9.3.9.4. Strategic initiatives
    • 9.3.10. Cook Medical
      • 9.3.10.1. Company overview
      • 9.3.10.2. Financial performance
      • 9.3.10.3. Product benchmarking
      • 9.3.10.4. Strategic initiatives
    • 9.3.11. Teleflex Incorporated
      • 9.3.11.1. Company overview
      • 9.3.11.2. Financial performance
      • 9.3.11.3. Product benchmarking
      • 9.3.11.4. Strategic initiatives
    • 9.3.12. Urotronic
      • 9.3.12.1. Company overview
      • 9.3.12.2. Financial performance
      • 9.3.12.3. Product benchmarking
      • 9.3.12.4. Strategic initiatives
    • 9.3.13. Coloplast Corp
      • 9.3.13.1. Company overview
      • 9.3.13.2. Financial performance
      • 9.3.13.3. Product benchmarking
      • 9.3.13.4. Strategic initiatives
    • 9.3.14. Richard Wolf GmbH
      • 9.3.14.1. Company overview
      • 9.3.14.2. Financial performance
      • 9.3.14.3. Product benchmarking
      • 9.3.14.4. Strategic initiatives
    • 9.3.15. PROCEPT BioRobotics Corporation
      • 9.3.15.1. Company overview
      • 9.3.15.2. Financial performance
      • 9.3.15.3. Product benchmarking
      • 9.3.15.4. Strategic initiatives
비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제